Evidence map›Paper›PMID 38731843›Full record

ArticleInternational journal of molecular sciences2024

Glycosylation and Characterization of Human Transferrin in an End-Stage Kidney Disease.

Goran Miljuš, Ana Penezić, Lucia Pažitná, Nikola Gligorijević, Marko Baralić, Aleksandra Vilotić, Miloš Šunderić, Dragana Robajac, Zorana Dobrijević, Jaroslav Katrlík and 1 more

Abstract read
In one paragraph

Article in International journal of molecular sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Glycosylation in kidney diseases.Precision clinical medicine · 2025
    Review
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Goran MiljušInstitute for the Application of Nuclear Energy (INEP), Department for Metabolism, University of Belgrade, 11000 Belgrade, Serbia.ORCID 0000-0001-6417-8711
Ana PenezićInstitute for the Application of Nuclear Energy (INEP), Department for Metabolism, University of Belgrade, 11000 Belgrade, Serbia.ORCID 0000-0002-2539-4507
Lucia PažitnáInstitute of Chemistry, Slovak Academy of Sciences, 84538 Bratislava, Slovakia.ORCID 0000-0003-2144-2476
Nikola GligorijevićInstitute of Chemistry, Technology and Metallurgy, Department of Chemistry, University of Belgrade, 11000 Belgrade, Serbia.ORCID 0000-0002-8691-2486
Marko BaralićSchool of Medicine, University of Belgrade, 11000 Belgrade, Serbia.ORCID 0000-0001-5585-9793
Aleksandra VilotićInstitute for the Application of Nuclear Energy (INEP), Department for Biology of Reproduction, University of Belgrade, 11000 Belgrade, Serbia.
Miloš ŠunderićInstitute for the Application of Nuclear Energy (INEP), Department for Metabolism, University of Belgrade, 11000 Belgrade, Serbia.ORCID 0000-0002-0940-9481
Dragana RobajacInstitute for the Application of Nuclear Energy (INEP), Department for Metabolism, University of Belgrade, 11000 Belgrade, Serbia.ORCID 0000-0002-6423-4645
Zorana DobrijevićInstitute for the Application of Nuclear Energy (INEP), Department for Metabolism, University of Belgrade, 11000 Belgrade, Serbia.ORCID 0000-0002-4652-7719
Jaroslav KatrlíkInstitute of Chemistry, Slovak Academy of Sciences, 84538 Bratislava, Slovakia.
Olgica NedićInstitute for the Application of Nuclear Energy (INEP), Department for Metabolism, University of Belgrade, 11000 Belgrade, Serbia.ORCID 0000-0003-2042-0056

Funding

Bilateral Cooperation project with the Republic of Slovakia 337-00-107/2019-09/12Ministry of Education, Science, Research and Sport of the Slovak Republic VEGA 2/0120/22Slovak Republic APVV SK-SRB-21-0046The ministry of science, technological development and innovation 451-03-47/2023-01/200019
6 · The paper itself

Abstract

Chronic kidney disease (CKD) is a global health concern affecting approximately one billion individuals worldwide. End-stage kidney disease (ESKD), the most severe form of CKD, is often accompanied by anemia. Peritoneal dialysis (PD), a common treatment for ESKD, utilizes the peritoneum for solute transfer but is associated with complications including protein loss, including transferrin (Tf) a key protein involved in iron transport. This study investigated Tf characteristics in ESKD patients compared to healthy individuals using lectin microarray, spectroscopic techniques and immunocytochemical analysis to assess Tf interaction with transferrin receptors (TfRs). ESKD patients exhibited altered Tf glycosylation patterns, evidenced by significant changes in lectin reactivity compared to healthy controls. However, structural analyses revealed no significant differences in the Tf secondary or tertiary structures between the two groups. A functional analysis demonstrated comparable Tf-TfR interaction in both PD and healthy samples. Despite significant alterations in Tf glycosylation, structural integrity and Tf-TfR interaction remained preserved in PD patients. These findings suggest that while glycosylation changes may influence iron metabolism, they do not impair Tf function. The study highlights the importance of a glucose-free dialysis solutions in managing anemia exacerbation in PD patients with poorly controlled anemia, potentially offering a targeted therapeutic approach to improve patient outcomes.

Indexed as

Kidney Failure, ChronicReceptors, TransferrinTransferrinAdultAgedFemaleGlycosylationHumansIronMaleMiddle AgedPeritoneal DialysisIronReceptors, TransferrinTransferrinend-stage kidney diseaseFTIRglycosylationlectin microarrayperitoneal dialysisstructuretransferrin

Identifiers

PMID38731843
PMCPMC11083005

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.